Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/1625
Título : Clinical aspects of melatonin intervention in Alzheimer's disease progression
Autor : Cardinali, Daniel Pedro 
Furio, Analía M. 
Brusco, Luis I. 
Palabras clave : MELATONINAENFERMEDAD DE ALZHEIMERENSAYO CLINICORITMO CIRCADIANOPRUEBAS NEUROPSICOLOGICAS
Fecha de publicación : 2010
Editorial : Bentham Science Publishers
Cita : Cardinali, D. P., Furio, A. M., Brusco, L. I. Clinical aspects of melatonin intervention in Alzheimer's disease progression [en línea]. Current Neuropharmacology. 2010, 8 (3). doi:10.2174/157015910792246209. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1625
Resumen : Abstract: Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day‐night rhythm disturbances like an agitated behavior during the evening hours (so‐called “sundowning”). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were “Alzheimer” and “melatonin”. Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad‐on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.
URI : https://repositorio.uca.edu.ar/handle/123456789/1625
ISSN : 1570-159X (impreso)
1875-6190 (online)
Disciplina: MEDICINA
DOI: 10.2174/157015910792246209
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
clinical-aspects-melatonin-intervention-alzheimer.pdf279,21 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

76
checked on Mar 4, 2021

Download(s)

49
checked on Mar 4, 2021

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons